Therapeutic Asset Ratings
3,774 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Adenovirus Specific T- Lymphocytes
Cytomegalovirus Infection
Jessie L. Alexander
P1/2
CCC
(48)
Adenovirus Specific T- Lymphocytes
Epstein-Barr Virus Infection
Jessie L. Alexander
P1/2
CCC
(48)
Admsc
Cognitive Disorder
Paul E Schulz
P1/2
CCC
(48)
Adoptive Therapy With Autologous Mc2 Tcr T Cells
Uveal Melanoma
Erasmus Medical Center
P1/2
CCC
(48)
Allo-501A
B-Cell Non-Hodgkin Lymphoma
Allogene Therapeutics
P1/2
CCC
(48)
Allogeneic Anti-Ny-Eso-1-Tcr-Il-15-Transduced Cord Blood-Derived Natural Killer Cells
Plasma Cell Myeloma
M.D. Anderson Cancer Center
P1/2
CCC
(48)
Allogeneic Car19 Regulatory T Cells
Hematopoietic And Lymphoid System Neoplasm
Masonic Cancer Center, University of Minnesota
P1/2
CCC
(48)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD
Chronic Myelomonocytic Leukemia
The First Affiliated Hospital with Nanjing Medical University
P1/2
CCC
(48)
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
Cirrhosis Of Liver
PT. Prodia Stem Cell Indonesia
P1/2
CCC
(48)
Allogeneic T Cell Progenitors, Cultured Ex-Vivo
Hematopoietic And Lymphoid System Neoplasm
Smart Immune SAS
P1/2
CCC
(48)
Allogenic Cd19 Car-̸̸̸̸T Cell
Non-Hodgkin Lymphoma
Chinese PLA General Hospital
P1/2
CCC
(48)
Allogenic Nk Cells
Acute Myeloid Leukemia
Xuzhou Medical University
P1/2
CCC
(48)
Allo-Quadcar01-T
Leukemia
AvenCell Therapeutics, Inc.
P1/2
CCC
(48)
Allo-Quadcar01-T
Diffuse Large B-Cell Lymphoma
AvenCell Therapeutics, Inc.
P1/2
CCC
(48)
Allo-Quadcar01-T
Lymphoma
AvenCell Therapeutics, Inc.
P1/2
CCC
(48)
Anti-Cd19 Anti-Cd20 Bispecific Car-T
B-Cell Acute Lymphoblastic Leukemia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
P1/2
CCC
(48)
Anti-Cd19 Autologous Car-T Cell Infusion
B-Cell Neoplasm
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
P1/2
CCC
(48)
Anti-Cd19/Cd22 Car-T Cells
Diffuse Large B Cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
P1/2
CCC
(48)
Anti-Cd19 Ucar-Nk Cells
B-Cell Acute Lymphoblastic Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
P1/2
CCC
(48)
Anti-Steap1 Car T-Cells
Castration-Resistant Prostate Carcinoma
Fred Hutchinson Cancer Center
P1/2
CCC
(48)
Autologous Cd19-Directed Chimeric Antigen Receptor T-Cells
Adult Acute Lymphoblastic Leukemia
University of Alberta
P1/2
CCC
(48)
Autologous Cd19-Directed Chimeric Antigen Receptor T-Cells
Non-Hodgkin Lymphoma
University of Alberta
P1/2
CCC
(48)
Autologous Cd19-Directed Chimeric Antigen Receptor T-Cells
Childhood Acute Lymphoblastic Leukemia
University of Alberta
P1/2
CCC
(48)
Autologous Cd1C+ /Cd141+ Mydc
Metastases to Soft Tissue
Universitair Ziekenhuis Brussel
P1/2
CCC
(48)
Autologous Dual-Target Car-T Cells Selected From The Predefined Target Library.
Refractory Malignant Neoplasm
Beijing Biotech
P1/2
CCC
(48)
Showing 626 to 650 of 3,774 assets
Previous
Page 26 of 151
Next